Table 1.
Demographic and baseline characteristics
| Characteristic | Study | |
|---|---|---|
| Narcolepsy | Obstructive sleep apnea | |
| Sample size (N) | 231 | 459 |
| Gender, n (%) | ||
| Female | 150 (64.9%) | 172 (37.5%) |
| Male | 81 (35.1%) | 287 (62.5%) |
| Age, year | ||
| Mean | 36.20 | 53.86 |
| SD | 13.15 | 10.96 |
| Range | 18–70 | 20–75 |
| Region, n (%) | ||
| Europe | 44 (19.0%) | 15 (3.3%) |
| North America | 187 (81.0%) | 444 (96.7%) |
| Race, n (%) | ||
| American Indian | 2 (0.9%) | 1 (0.2%) |
| Asian | 6 (2.6%) | 17 (3.7%) |
| Black | 33 (14.3%) | 87 (19.0%) |
| Multiple | 5 (2.2%) | 4 (0.9%) |
| Pacific Islander | 1 (0.4%) | 2 (0.4%) |
| White | 184 (79.7%) | 348 (75.8%) |
| Ethnicity, n (%) | ||
| Hispanic | 10 (4.3%) | 40 (8.7%) |
| Not Hispanic | 221 (95.7%) | 419 (91.3%) |
| Mean (SD) FOSQ-10 score | 11.7 (3.03) | 13.9 (3.01) |
| Mean (SD) ESS score | 17.2 (3.18) | 15.2 (3.32) |
| Mean MWT sleep latency, mina,b | 6.2–8.7c | 12.1–13.6c |
SD, standard deviation; FOSQ-10, Functional Outcomes of Sleep Questionnaire-10; ESS, Epworth Sleepiness Scale; MWT, Maintenance of Wakefulness Test; OSA, obstructive sleep apnea
aInclusion criteria included baseline MWT sleep latency < 25 min for participants with narcolepsy and < 30 min for participants with OSA
bNarcolepsy, n = 227 (placebo, n = 57; combined solriamfetol, n = 170); OSA, n = 450 (placebo, n = 111; combined solriamfetol, n = 339)
cRange across all treatment groups